Betta Pharmaceuticals Future Growth
Future criteria checks 4/6
Betta Pharmaceuticals is forecast to grow earnings and revenue by 26.7% and 18.5% per annum respectively. EPS is expected to grow by 26.8% per annum. Return on equity is forecast to be 10.8% in 3 years.
Key information
26.7%
Earnings growth rate
26.8%
EPS growth rate
| Pharmaceuticals earnings growth | 19.3% |
| Revenue growth rate | 18.5% |
| Future return on equity | 10.8% |
| Analyst coverage | Good |
| Last updated | 04 Nov 2024 |
Recent future growth updates
Recent updates
We Think That There Are Some Issues For Betta Pharmaceuticals (SZSE:300558) Beyond Its Promising Earnings
Nov 04
Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Still On The Mark Following 29% Share Price Bounce
Sep 30Results: Betta Pharmaceuticals Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 07Unpleasant Surprises Could Be In Store For Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Shares
Jul 30These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Reasonably Well
Jul 05Betta Pharmaceuticals' (SZSE:300558) Earnings Are Weaker Than They Seem
Apr 26Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts
Apr 23What Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Not Telling You
Apr 16Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4,497 | 850 | 1,908 | 991 | 6 |
| 12/31/2025 | 3,719 | 651 | 1,525 | 1,304 | 6 |
| 12/31/2024 | 3,137 | 534 | 1,029 | 529 | 2 |
| 9/30/2024 | 2,757 | 460 | 311 | 1,186 | N/A |
| 6/30/2024 | 2,643 | 424 | 164 | 1,076 | N/A |
| 3/31/2024 | 2,660 | 395 | -80 | 1,023 | N/A |
| 12/31/2023 | 2,456 | 348 | -182 | 914 | N/A |
| 9/30/2023 | 2,757 | 347 | -304 | 657 | N/A |
| 6/30/2023 | 2,437 | 199 | -588 | 539 | N/A |
| 3/31/2023 | 2,324 | 113 | -623 | 415 | N/A |
| 12/31/2022 | 2,377 | 145 | -704 | 307 | N/A |
| 9/30/2022 | 2,184 | 139 | -797 | 276 | N/A |
| 6/30/2022 | 2,344 | 263 | -530 | 426 | N/A |
| 3/31/2022 | 2,212 | 319 | -373 | 478 | N/A |
| 1/1/2022 | 2,246 | 383 | -232 | 527 | N/A |
| 9/30/2021 | 2,087 | 439 | -95 | 616 | N/A |
| 6/30/2021 | 2,074 | 678 | -227 | 521 | N/A |
| 3/31/2021 | 1,842 | 624 | -317 | 439 | N/A |
| 12/31/2020 | 1,870 | 606 | -40 | 646 | N/A |
| 9/30/2020 | 1,818 | 546 | -22 | 656 | N/A |
| 6/30/2020 | 1,744 | 287 | 150 | 671 | N/A |
| 3/31/2020 | 1,826 | 310 | 220 | 739 | N/A |
| 12/31/2019 | 1,554 | 231 | -65 | 555 | N/A |
| 9/30/2019 | 1,540 | 218 | -178 | 448 | N/A |
| 6/30/2019 | 1,405 | 187 | -291 | 375 | N/A |
| 3/31/2019 | 1,314 | 176 | -368 | 314 | N/A |
| 12/31/2018 | 1,224 | 167 | -328 | 286 | N/A |
| 9/30/2018 | 1,186 | 202 | -322 | 313 | N/A |
| 6/30/2018 | 1,110 | 187 | N/A | 316 | N/A |
| 3/31/2018 | 1,081 | 225 | N/A | 282 | N/A |
| 12/31/2017 | 1,026 | 258 | N/A | 278 | N/A |
| 9/30/2017 | 1,016 | 264 | N/A | 276 | N/A |
| 6/30/2017 | 1,015 | 294 | N/A | 302 | N/A |
| 3/31/2017 | 990 | 341 | N/A | 355 | N/A |
| 12/31/2016 | 1,035 | 369 | N/A | 407 | N/A |
| 9/30/2016 | 987 | 364 | N/A | 400 | N/A |
| 12/31/2015 | 915 | 345 | N/A | 386 | N/A |
| 12/31/2014 | 704 | 271 | N/A | 278 | N/A |
| 12/31/2013 | 481 | 180 | N/A | 190 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300558's forecast earnings growth (26.7% per year) is above the savings rate (2.8%).
Earnings vs Market: 300558's earnings (26.7% per year) are forecast to grow faster than the CN market (25.9% per year).
High Growth Earnings: 300558's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 300558's revenue (18.5% per year) is forecast to grow faster than the CN market (13.8% per year).
High Growth Revenue: 300558's revenue (18.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 300558's Return on Equity is forecast to be low in 3 years time (10.8%).